Details of Data Requests to Use Johnson and Johnson Data

Request listing updated daily

All Requests

The YODA Project posts proposals once data access has been granted or denied.

Approved Requests

The YODA Project posts approved proposals once data access has been granted.

Withdrawn Requests

The following data requests could not be fulfilled due to patient privacy concerns, data element availability, data security concerns, or lack of research proposal clarity. The YODA Project posts withdrawn/unapproved proposals at the time the decision is made.

Filters list

Search By Protocol Number

Product of Interest

PI Country

PI Affiliation

Year of Data Access

NO. Trials Provided

Results

Project Status

YODA Protocol Number 2022-5104
Product(s) of Interest REMICADE® (Infliximab) SIMPONI® (Golimumab) STELARA® (Ustekinumab)
NO. Trials Provided 6
Publication Available! Published Biomarkers for Predicting Long-term Outcomes in Ulcerative Colitis Principal Investigator Rirong Chen The first affiliated hospital of Sun Yet-sen University Reports and Publications Fecal lactoferrin early predicts long-term outcomes in ulcerative colitis: A post-hoc analysis of the UNIFI and PURSUIT trials
YODA Project Review Due Diligence Assessment
YODA Protocol Number 2021-4846
Product(s) of Interest ERLEADA® (Apalutamide)
NO. Trials Provided 1
Publication Available! Published External Validation of a Prognostic Model of Overall Survival In Men with Metastatic Castration-Resistant Prostate Cancer Principal Investigator Susan Halabi Duke University Reports and Publications J Clin Oncol . 2023
YODA Project Review Due Diligence Assessment
YODA Protocol Number 2021-4822
Product(s) of Interest STELARA® (Ustekinumab)
NO. Trials Provided 2
Publication Available! Ongoing Comparative Efficacy of Ustekinumab and Infliximab on One Year Outcomes Among Biologic-nave Induction Responders in Crohn?s Disease Principal Investigator Neeraj Narula Hamilton Health Sciences Reports and Publications Inflamm Bowel Dis. 2022
View 1 Citations
YODA Project Review Due Diligence Assessment
YODA Protocol Number 2021-4779
Product(s) of Interest REMICADE® (Infliximab) STELARA® (Ustekinumab) SIMPONI® (Golimumab)
NO. Trials Provided 6
Publication Available! Published Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn?s Disease Principal Investigator Neeraj Narula Hamilton Health Sciences Reports and Publications Clin Gastroenterol Hepatol . 2022
View 1 Citations
YODA Project Review Due Diligence Assessment
YODA Protocol Number 2021-4778
Product(s) of Interest STELARA® (Ustekinumab)
NO. Trials Provided 3
Publication Availible! Published Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn?s Disease Principal Investigator Neeraj Narula Hamilton Health Sciences Reports and Publications AJG 2022
View 14 Citations
YODA Project Review Due Diligence Assessment
YODA Protocol Number 2021-4757
Product(s) of Interest REMICADE® (Infliximab)
NO. Trials Provided 2
Publication Available! Published A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis. Principal Investigator Neeraj Narula Hamilton Health Sciences Reports and Publications Digestive Diseases and Sciences
YODA Project Review Due Diligence Assessment
YODA Protocol Number 2021-4684
Product(s) of Interest STELARA® (Ustekinumab)
NO. Trials Provided 3
Publications Available! (see more below) Published Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn?s Disease Principal Investigator Neeraj Narula Hamilton Health Sciences Reports and Publications Aliment Pharmacol Ther. 2022 | J Chron’s Colitis. 2022
View 2 Citations
YODA Project Review Due Diligence Assessment
YODA Protocol Number 2021-4637
Product(s) of Interest SPRAVATO® (Esketamine)
NO. Trials Provided 3
Publication Available! Published Data-sharing and re-analysis for main studies assessed by the European Medicines Agency – a cross-sectional study on EPARs Principal Investigator Florian Naudet University of Rennes 1 Reports and Publications BMC 2023
YODA Project Review Due Diligence Assessment
YODA Protocol Number 2021-4602
Product(s) of Interest STELARA® (Ustekinumab) REMICADE® (Infliximab)
NO. Trials Provided 4
Publication Available! Published Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn?s Disease Principal Investigator Neeraj Narula Hamilton Health Sciences Reports and Publications Journal of Chron’s & Colitis
View 3 Citations
YODA Project Review Due Diligence Assessment
YODA Protocol Number 2021-4599
Product(s) of Interest DARZALEX® (Daratumumab)
NO. Trials Provided 6
Publication Available! Published Outcomes with Early versus Late Response to Daratumumab in Patients with Refractory/Relapsed or Newly Diagnosed Multiple Myeloma Principal Investigator Jiasheng Wang MetroHealth Medical Center Reports and Publications Leuk Lymphoma 2022
View 2 Citations
YODA Project Review Due Diligence Assessment